Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BCVA”

25 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 25 results

Large-scale testing (Phase 3)Study completedNCT01512966
What this trial is testing

Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema)

Who this might be right for
Macular Edema
Bayer 73
Not applicableStudy completedNCT01840683
What this trial is testing

HELP Therapy for Dry AMD

Who this might be right for
Non-exudative (Dry) Age-related Macular Degeneration (AMD)
B.Braun Avitum AG 22
Not applicableUnknownNCT01581151
What this trial is testing

Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion

Who this might be right for
Retinal Vein Occlusion
Brian Burke, MPH 30
Not applicableStudy completedNCT01247155
What this trial is testing

First Postoperative Day Review After Uneventful Phacoemulsification

Who this might be right for
PhacoemulsificationComplicationsBCVA
Veroia General Hospital
Post-approval studies (Phase 4)Study completedNCT01988662
What this trial is testing

UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD)

Who this might be right for
Neovacular Age-related Macular Degeneration
Novartis Pharmaceuticals 205
Large-scale testing (Phase 3)Study completedNCT03610646
What this trial is testing

Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME)

Who this might be right for
Diabetic Macular Edema
Mylan Pharmaceuticals Inc 355
Not applicableLooking for participantsNCT06805474
What this trial is testing

A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT

Who this might be right for
Macular DegenerationGeographic AtrophyStargardt Disease
Nanoscope Therapeutics Inc. 30
Not applicableStudy completedNCT01269151
What this trial is testing

Ranibizumab Short- and Log-term Effects on Retinal Function in wAMD

Who this might be right for
Age-Related Macular DegenerationRetinal Function
University of Luebeck 20
Post-approval studies (Phase 4)Study completedNCT01958918
What this trial is testing

Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD

Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 712
Early research (Phase 1)Looking for participantsNCT04289571
What this trial is testing

Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease

Who this might be right for
Cone-Rod DegenerationRod-Cone Degeneration
National Eye Institute (NEI) 165
Not applicableNot Yet RecruitingNCT07171541
What this trial is testing

Correlation Between OCT and Mf-ERG Findings With BCVA in Patients With Macular Dystrophy

Who this might be right for
Macular Dystrophy
New Valley University 30
Not applicableStudy completedNCT01370135
What this trial is testing

Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma

Who this might be right for
Neovascular GlaucomaRubeosis
University of Luebeck 20
Post-approval studies (Phase 4)Study completedNCT01986907
What this trial is testing

Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye

Who this might be right for
Wet Age Related Macular Degeneration
Novartis Pharmaceuticals 1,049
Post-approval studies (Phase 4)Study completedNCT01722045
What this trial is testing

Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)

Who this might be right for
Age - Related Macular Degeneration (AMD)
Regeneron Pharmaceuticals 154
Post-approval studies (Phase 4)Study completedNCT02953938
What this trial is testing

Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety

Who this might be right for
Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
Novartis Pharmaceuticals 59
Not applicableStudy completedNCT04018833
What this trial is testing

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema

Who this might be right for
Diabetic Macular EdemaDiabetic Retinopathy
Bernardete Pessoa MD 40
Large-scale testing (Phase 3)Study completedNCT01783886
What this trial is testing

Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement

Who this might be right for
Macular Edema
Bayer 381
Not applicableLooking for participantsNCT07613580
What this trial is testing

Assessing Agreement Between Acuvera Capture and Paper-Based Methods for BCVA Data Recording in Ophthalmic Trials

Who this might be right for
Ophthalmopathy
OptymEdge, LLC 90
Not applicableStudy completedNCT04820218
What this trial is testing

At-home Testing Refraction Results With Best Corrected Visual Acuity (BCVA) Outcomes in Adults

Who this might be right for
Visual ImpairmentMyopiaHyperopia+1 more
EyeQue Corp. 53
Not applicableStudy completedNCT01614158
What this trial is testing

Assessment of Visual Field-related Endpoints in Patients With Non-arteritic Ischemic Optic Neuropathy

Who this might be right for
Non-arteritic Ischemic Optic Neuropathy
University Hospital Tuebingen 16
Next Page